Overview

CSF Pharmacokinetics of Ondansetron

Status:
Completed
Trial end date:
2016-11-17
Target enrollment:
Participant gender:
Summary
Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability that may affect that distribution. Study procedures will include iv ondansetron administration, serial blood draws, cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.
Phase:
N/A
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Ondansetron